Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity

Raj, Ruhi; Wairkar, Sarika; Sridhar, Vinay; Gaud, Ram

doi:10.1016/j.ijbiomac.2017.12.056

Cited by 153 publications

(64 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, HMS/Prami/Alg did not show any protection in H 2 O 2 induced injury of neuronal SH-SY5Y cells ( Figure 11(e)). Our observations on enhanced antioxidant activity of chitosan-containing particles loaded with pramipexole supported a recent report by Raj et al [65]. The authors reported a superior pharmacological antioxidant effect of pramipexole-loaded chitosan nanoparticles for intranasal administration, measured as increased superoxide dismutase and catalase activities in rat brain tissue homogenates [65].…”

Section: Protective Effects Of Pramipexol Loaded Hms Formulations On supporting

confidence: 91%

Development andin vitrosafety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Tzankov

Voycheva

Yordanov

et al. 2019

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

Section: Protective Effects Of Pramipexol Loaded Hms Formulations On supporting

confidence: 91%

Development andin vitrosafety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Tzankov

Voycheva

Yordanov

et al. 2019

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…Compared to an intranasal solution, quetiapine chitosan nanoparticles enhanced the drug delivery to the brain by 34% [179]. It has been reported that intranasal chitosan nanoparticles of pramipexole better controlled motor deficits in a rotenone model of PD than the oral or solution dosage form of the drug [195]. Additionally, chitosan nanoparticles have also been shown to be used in gene therapies via nasal administration.…”

Section: Nanoparticles Composed Of Chitosan and Chitosan Derivativesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

Although the global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery of drug molecules in therapeutic quantities to the central nervous system (CNS) is still lacking. The blood brain barrier (BBB) is the major obstacle for the entry of drugs into the brain, as it comprises a tight layer of endothelial cells surrounded by astrocyte foot processes that limit drugs' entry. In recent times, intranasal drug delivery has emerged as a reliable method to bypass the BBB and treat neurological diseases. The intranasal route for drug delivery to the brain with both solution and particulate formulations has been demonstrated repeatedly in preclinical models, including in human trials. The key features determining the efficacy of drug delivery via the intranasal route include delivery to the olfactory area of the nares, a longer retention time at the nasal mucosal surface, enhanced penetration of the drugs through the nasal epithelia, and reduced drug metabolism in the nasal cavity. This review describes important neurological disorders, challenges in drug delivery to the disordered CNS, and new nasal delivery techniques designed to overcome these challenges and facilitate more efficient and targeted drug delivery. The potential for treatment possibilities with intranasal transfer of drugs will increase with the development of more effective formulations and delivery devices. Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neurodegenerative disease, leading to the development of bradykinesia and tremors of cardinal motor functions ( Figure 2) [3]. PD models specifically show a decrease in dopamine transporters, which are responsible for dopamine uptake by dopaminergic neurons and progression of neuronal communications. Reduced Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neuro...

show abstract

“…The brain C max was estimated at 0.056% of the administered dose of 2.3 mg kg 21 with the nanoparticle formulation and 0.03% of the administered dose with the solution of the drug. The use of intranasal chitosan nanoparticles containing pramipexole corrected motor deficits in a rotenone model of Parkinson's disease, and pharmacodynamic effects were superior in the nanoparticle-administered animals when compared with a nasal solution or an oral dosage form of the drug (Raj et al, 2018). In all of these preclinical studies, the demonstration of drug delivery to the brain with pharmacokinetics data plus pharmacodynamic responses provides confidence in the approach (Godfrey et al, 2018;Raj et al, 2018).…”

Section: Nanoparticlesmentioning

confidence: 97%

Nose-to-Brain Delivery

Wang¹,

Xiong²,

Tsang³

et al. 2019

J Pharmacol Exp Ther

168

View full text Add to dashboard Cite

The global prevalence of neurologic disorders is rising, and yet we are still unable to deliver most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists of a tight layer of endothelial cells surrounded by astrocyte foot processes, and these anatomic features constitute a significant barrier to drug transport from the blood to the brain. One way to bypass the blood brain barrier and thus treat diseases of the brain is to use the nasal route of administration and deposit drugs at the olfactory region of the nares, from where they travel to the brain via mechanisms that are still not clearly understood, with travel across nerve fibers and travel via a perivascular pathway both being hypothesized. The nose-to-brain route has been demonstrated repeatedly in preclinical models, with both solution and particulate formulations. The nose-to-brain route has also been demonstrated in human studies with solution and particle formulations. The entry of device manufacturers into the arena will enable the benefits of this delivery route to become translated into approved products. The key factors that determine the efficacy of delivery via this route include the following: delivery to the olfactory area of the nares as opposed to the respiratory region, a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia, and a reduction in drug metabolism in the nasal cavity. Indications where nose-to-brain products are likely to emerge first include the following: neurodegeneration, posttraumatic stress disorder, pain, and glioblastoma.

show abstract

Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity

Cited by 153 publications

References 43 publications

Development andin vitrosafety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Development andin vitrosafety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Nose-to-Brain Delivery

Contact Info

Product

Resources

About